Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,567 | 260 | 2,261 |
| Samples | 391 | 66 | 318 |
| Peptides | 293 | 42 | 257 |
Function
DCX · Doublecortin
This gene encodes a member of the doublecortin family. The protein encoded by this gene is a cytoplasmic protein and contains two doublecortin domains, which bind microtubules. In the developing cortex, cortical neurons must migrate over long distances to reach the site of their final differentiation. The encoded protein appears to direct neuronal migration by regulating the organization and stability of microtubules. In addition, the encoded protein interacts with LIS1, the regulatory gamma subunit of platelet activating factor acetylhydrolase, and this interaction is important to proper microtubule function in the developing cortex. Mutations in this gene cause abnormal migration of neurons during development and disrupt the layering of the cortex, leading to epilepsy, cognitive disability, subcortical band heterotopia ('double cortex' syndrome) in females and lissencephaly ('smooth brain' syndrome) in males. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2010].
Isoforms & Proteins
9 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000636035 | A0A1C7CYW0* | 402 | 245 |
| ENST00000356220 | A0A1C7CYW0* | 368 | 235 |
| ENST00000635795 | O43602 | 368 | 235 |
| ENST00000637453 | A0A1C7CYW0* | 368 | 235 |
| ENST00000637570 | A0A1B0GWD1* | 359 | 229 |
| ENST00000488120 | O43602-2 | 358 | 228 |
| ENST00000371993 | A0A804CF28* | 321 | 200 |
| ENST00000358070 | A0A9S7JGE9* | 13 | 9 |
| ENST00000496551 | A0A9S7N7F7* | 10 | 6 |
Gene Properties
Recurrent Mutations
All 235 amino-acid changes on canonical ENST00000635795 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in DCX · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in DCX – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 23/612 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Melanoma | 5/210 2% | 66/1899 3% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 21/810 3% |
| Other Solid Cancers | 2/94 2% | 37/1515 2% |
| Non-Small Cell Lung Carcinoma | 13/304 4% | 21/1390 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 12/752 2% |
| Colorectal Carcinoma | 17/143 12% | 35/3239 1% |
| Neuroendocrine Tumour | 6/154 4% | 2/577 0% |
| Cervical Carcinoma | 1/35 3% | 3/422 1% |
| Mesothelioma | 0/62 0% | 2/165 1% |
| Gastric Carcinoma | 1/74 1% | 13/1809 1% |
| Hepatocellular Carcinoma | 3/46 7% | 12/2210 1% |
| Ovarian Carcinoma | 3/109 3% | 4/998 0% |
| Head and Neck Carcinoma | 2/85 2% | 8/1574 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 12/2550 0% |
| Glioma | 0/52 0% | 10/2127 0% |
| Non-Cancerous | 1/104 1% | 3/830 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| Prostate Carcinoma | 0/13 0% | 6/2105 0% |
| Pancreatic Carcinoma | 1/89 1% | 3/1611 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 6/2534 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Bladder Carcinoma | 0/58 0% | 2/956 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 3/1592 0% |
Mutation Distribution
Where DCX is mutated · all tissues, split by cell line vs tissue
How many mutations in DCX were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 48 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,567 mutations in DCX
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|